Clinical trial
Surgery or Radiotherapy After PD-L1 Inhibitor (TQB-2450) and Chemotherapy Induction Therapy in Patients With Limited-stage Small-cell Lung Cancer
NCT04539977 is registered in ClinicalTrials.gov with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Surgery or Radiotherapy After PD-L1 Inhibitor (TQB-2450) and Chemotherapy Induction Therapy in Patients With Limited-stage Small-cell Lung Cancer
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 1, 2020
- Completion date
- December 31, 2028
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
small-cell lung cancer